Celator Pharmaceuticals (NASDAQ: CPXX) and Infinity Pharmaceuticals (NASDAQ:INFI) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitabiliy, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Institutional & Insider Ownership

76.5% of Infinity Pharmaceuticals shares are owned by institutional investors. 6.8% of Infinity Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Celator Pharmaceuticals and Infinity Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celator Pharmaceuticals 0 0 0 0 N/A
Infinity Pharmaceuticals 0 4 0 0 2.00

Infinity Pharmaceuticals has a consensus target price of $1.00, indicating a potential downside of 28.57%. Given Infinity Pharmaceuticals’ higher probable upside, analysts clearly believe Infinity Pharmaceuticals is more favorable than Celator Pharmaceuticals.

Volatility and Risk

Celator Pharmaceuticals has a beta of 7.09, suggesting that its stock price is 609% more volatile than the S&P 500. Comparatively, Infinity Pharmaceuticals has a beta of 2.63, suggesting that its stock price is 163% more volatile than the S&P 500.

Earnings & Valuation

This table compares Celator Pharmaceuticals and Infinity Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Celator Pharmaceuticals N/A N/A N/A ($0.59) -51.25
Infinity Pharmaceuticals $9.47 million 7.46 -$88.20 million ($0.01) -140.00

Celator Pharmaceuticals has higher revenue, but lower earnings than Infinity Pharmaceuticals. Infinity Pharmaceuticals is trading at a lower price-to-earnings ratio than Celator Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Celator Pharmaceuticals and Infinity Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celator Pharmaceuticals N/A -75.03% -46.70%
Infinity Pharmaceuticals N/A -77.26% -51.26%

Summary

Infinity Pharmaceuticals beats Celator Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

About Celator Pharmaceuticals

Celator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company’s technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity. The Company’s product, VYXEOS, a nano-scale liposomal formulation of cytarabine:daunorubicin, in Phase III clinical testing for the treatment of acute myeloid leukemia. The Company also conducted clinical development efforts on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer; and has a preclinical stage product candidate CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. The Company operates in the United States and Canada.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Receive News & Ratings for Celator Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celator Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.